Elevated levels of IL-8 in fatal leptospirosis

• Main Authors: Abdullah, M. (Author), Amin Nordin, S. (Author), Amran, F. (Author), Md. Shah, A. (Author), Mohd Taib, N. (Author), Sekawi, Z. (Author), Wan Yusoff, W.S.Y (Author), Yuhana, M.Y (Author)
• Format: Article
• Language: English
• Published: Taylor and Francis Ltd., 2020
• Subjects: adolescent; Adolescent; adult; Adult; aged; Aged; alanine aminotransferase; Article; aspartate aminotransferase; biological marker; blood; C reactive protein; clinical Outcomes; controlled study; cytokine; cytokines; disease severity; female; Female; human; Humans; IL-8; interleukin 10; interleukin 6; interleukin 8; Interleukin-8; leptospirosis; Leptospirosis; major clinical study; malaysia; Malaysia; male; Male; middle aged; Middle Aged; mortality; multiple organ failure; neutrophil; protein expression; tumor necrosis factor; young adult; Young Adult
• Online Access: View Fulltext in Publisher; View in Scopus

 Leptospirosis causes a wide range of clinical outcomes, including organ failure and death. Early treatment significantly increases the chances of cure. Interleukin-8 (IL-8) is a chemoattractant cytokine for neutrophil and is associated with multiple organ failure. Research has indicated IL-8 to be raised in severe and fatal cases of leptospirosis, but its suitability as a prognostic biomarker has yet to be confirmed. This study aimed to evaluate the significance of IL-8 with the clinical outcomes of leptospirosis patients. Plasma IL-8 was measured in fifty-two samples from hospitalized patients and nineteen healthy controls. The comparisons were made between mild, severe-survived and fatal groups identified by clinical or laboratory findings. IL-8 was significantly higher in fatal (p = 0.01) compared to mild cases. IL-8 was also significantly higher in fatal (p = 0.02) when compared to survived cases of leptospirosis. IL-8 levels in the plasma of fatal leptospirosis cases were significantly elevated compared to survived cases and may serve as a potential prognostic biomarker in determining the possible outcome of leptospirosis patients. © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group.